Home Banner r050616 550px

Despite remarkable advances in treatment and prevention, HIV/AIDS is neither contained nor manageable. In 2015 alone, AIDS killed more than 1 million people globally and HIV newly infected more than 2 million people, with two-thirds of them in sub-Saharan Africa. Annual new infections with HIV have not decreased for years. Access and adherence to available prevention and treatment remain challenging for many. Innovation in HIV prevention and a vaccine are needed to end AIDS.

The HIV R4P 2016 conference, 17-21 October in Chicago, will gather 1,500 leaders in HIV prevention research, programs, and policy to share latest progress and look at future steps.

Click session dates for full details

Tuesday, 18 October - VACCINE-INDUCED HUMORAL IMMUNITY - Chris Parks (Symposium), SY01

Protection from Rectal SHIV Infection Induced by Mucosal Vaccination with a Replication-competent VSV-HIV Chimera Delivering Env Trimers - Chris Parks
Date: Tuesday, 18 October
Time: 15:52-16:14
Venue: Sheraton Grand Chicago, Chicago Ballroom VI-VII

Wednesday, 19 October - USING ARVS AND ANTIBODIES FOR LONG-ACTING PREVENTION - Frances Priddy (Symposium), SY05

AAV and Other Novel Antibody Delivery Platforms - Frances Priddy
Date: Wednesday, 19 October
Time: 16:14-16:36
Venue: Sheraton Grand Chicago, Sheraton Ballroom IV-V

Thursday, 20 October - GETTING IT RIGHT: THE JOURNEY FROM DISCOVERY TO IMPACT - Maggie Keane (Round Table), RT04

When We Got It Right and When We Got It Wrong - Maggie Keane
Date: Thursday, 20 October
Time: 8:30-8:40
Venue: Sheraton Grand Chicago, Chicago Ballroom VIII-X


Click to expand full details

Monday, 17 October

Panel: Target Product Profile for HIV Vaccines
Time: 13:00-15:00
Speakers: Dagna Laufer, Jim Ackland
Location: Erie Room

Tuesday, 18 October

Session: Antibody Epitopes: Connecting the Dots
Time: 10:30 -10:45
Location: Sheraton Ballroom II-III
Oral Presenation: "A prominent site of antibody vulnerability on HIV Env incorporates the CCR5 coreceptor site and its camouflaging glycans"
Speaker: Devin Sok

Session: Risky Business
Time: 13:00 - 14:30
Location: Sheraton Ballroom II-III
Session Co-Chair: Frances Priddy

Oral Presenation: "Behavioral and biological risk factors among MSM in Kigali, Rwanda"
Time: 13:00 - 13:15
Speaker: Julien Nyombayire

Session: A Sugar Coated Pill: Immunogenicity of Envelope
Time: 13:15 - 13:30
Location: Chicago Ballroom VII-X
Oral Presentation: "Priming a VRC01-like antibody response in human immunoglobulin locus transgenic mice"
Speaker: Devin Sok

Session: Vaccine-Induced Humural Immunity
Time: 15:52-16:14
Location: Chicago Ballroom VI-VII
Oral Presentation: "Protection from rectal SHIV infection induced by mucosal vaccination with a replication-competent VSV-HIV chimera delivering Env trimers"
Speaker: Chris Parks

Session: Evaluation of Vaccine Concepts
Time: 17:15 - 18:00
Location: Sheraton Ballroom IV-V
Co-Chair: Anatoli Kamali

Oral Poster: "Recombinant Sendai Vaccine Delivered Mucosally Induces Gag-specific Functional T-cells or Antibody Responses in Prime-boost Regimens in Humans"
Time: 17:15 - 17:24
Speaker: Julien Nyombayire

Oral Poster: "EV06 Trial: Modulation of the Immunogenicity of the DNA-HIV-PT123 and AIDSVAX® B/E combination HIV vaccine in adult Ugandans by S. mansoni Infection"
Time: 17:51 - 18:00
Speaker: Pietro Pala

Wednesday, 19 October

Session: HIV Antibodies: The Good, The Bad and the Ugly
Time: 10:30-12:00
Location: Sheraton Ballroom II-III
Session Co-Chair: Elise Landais

Oral Presentation: "Characterization of the Early Antibody Landscape In HIV 1 Infected Individuals Who Develop Poor to Elite Levels of Neutralization Breadth"
Time: 10:30 - 10:45
Speaker: S. Abigail Smith

Session: Back to the Future: Optimizing the Cascade
Time: 10:45 - 11:00
Location: Sheraton Ballroom IV-V
Oral Presentation: "High uptake of antiretroviral treatment among Female Sex Workers in Kigali, Rwanda"
Speaker: Etienne Karita

Session: Do Right to Do Well: Creating a Framework for Success
Location: Sheraton Ballroom II-III

Oral Presentation: "Harmonization of Regulatory Framework for Control of Clinical Trials in East Africa: Progress, Challenges and Lessons Learnt"
Time: 13:00 - 13:15
Speaker: Jane Humphrey Mashingia

Oral Presentation
: "Improving the Efficiency of African Research Ethics Committees and Standardizing Ethics Review processes – through an Automated review platform"
Time: 13:45 - 14:00
Speaker: Boitumelo Mokgatla

Oral Presentation: "Toward Innovation in HIV Prevention: Sustaining Funding in a Post-2015 Landscape"
Time: 14:00 - 14:15
Speaker: Laura Marie Lazar

Session: PrEP and the Real World
Location: Chicago Ballroom VIII-X

Oral Presentation: "Feasibility of conducting HIV combination intervention effectiveness trials in fishing communities in Uganda: a cluster randomized pilot"
Time: 14:00 - 14:15
Speaker: Peter Mugo

Session: Teaching the Immune System New Tricks: Vaccine-Induced Immune Responses
Location: Sheraton Ballroom IV-V

Oral Presentation: "Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults"
Time: 14:00 - 14:15
Speaker: Joesphine Cox

Session:  Pushing the Envelope
Location: Sheraton Ballroom IV-V

Oral Poster: "Common Env escape drives the maturation of V2-apex targeting bnAbs in HIV-1 infected individuals"
Time: 17:15 – 17:24
Presenter: Elise Landais

Oral Poster: "Direct access to the co-receptor binding site in virus is dependent on mass of the inhibitory molecule and the length of variable loops, V1/V2 of Env"
Presenter: Bimal K Chakrabarti
Time: 17:24 – 17:33
Presenter: Bimal K Chakrabarti

Thursday, 20 October

Session: The Great Escape: Host-Virus Transmission Dynamics
Location: Sheraton Ballroom IV-V

Oral Presentation: "Gender Differences in Transmission of HIV-1 Viral Variants and Their Impact on Early Immune Activation"
Time: 10:30 - 10:45
Speaker: Elina El-Badry

Oral Presentation: "Transmission of Multiple HIV-1 Founder Viruses and High Frequency of Unique Recombinant Forms among MSM in Kenya"
Time: 11:00 - 11:15
Speaker: Gladys Macharia

Session: Power, Pleasure and Prevention
Location: Chicago Ballroom VI-VII

Oral Presentation: "Happy Clients: a model for promoting Long Acting Reversible Contraceptives"
Time: 13:00 - 13:15
Speaker: Alexandra Hoagland

Oral Presentation: "Effectiveness of integrated HIV Prevention and Family Planning Services for Couples in Zambia to Prevent HIV and Unintended Pregnancy"
Time: 13:30 - 13:45
Speaker: Mubiana Inambao

Click session titles for full details

Monday, 17 Oct: Vaccine Design & Development Partnerships in Africa

HIV Vaccine Design and Development Partnerships in Africa:
Showcasing African-led Basic HIV Prevention Science Research

Date: Monday, 17 October
Time: 8:30-12:30
Venue: Sheraton Grand Chicago, Chicago Ballroom IX
Co-hosts: Global HIV Vaccine Enterprise, MRC/UVRI Uganda Research Unit on AIDS, IAVI

This session will bring together African and international scientists, policy makers, advocates and institutions involved in HIV prevention research. They will take a look at current design and development partnership models to identify success factors, gaps and opportunities for enhanced collaborations, as well as young scientists. Presenters and participants will be invited to share their ideas of the next priorities for African HIV prevention research. These will be discussed in a panel discussion on the way forward.

Session Chairs:
Pontiano Kaleebu, Medical Research Council/Uganda Virus Research Institute
Peter Dukes, Deputy Director, Africa Research Excellence Fund, The Gambia/Uganda/UK

Jill Gilmour, International AIDS Vaccine Initiative
Gladys Macharia, Kenya Medical Research Institute
Amin Hassan, Kenya Medical Research Institute

Glenda Gray, Medical Research Council, South Africa
Fatima Laher, Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, South Africa
Jinal Bhiman, National Institute for Communicable Diseases, South Africa

Thomas Nyirenda, European & Developing Countries Clinical Trials Partnership
Sabelle Jallow, Medical Research Council, The Gambia
Loveline Ngu, Chantal Biya International Reference Center for Research on the Prevention and Management of HIV/AIDS, Cameroon

Peter Dukes, Africa Research Excellence Fund, The Gambia/Uganda/UK

Pontiano Kaleebu, Medical Research Council/Uganda Virus Research Institute

Session Chairs:
Margaret McCluskey, U.S. Agency for International Development
William Snow, Global HIV Vaccine Enterprise

Nelson Michael, U.S. Military HIV Research Program
Elioda Tumwesigye, Minister of Science and Technology, Uganda
Thumbi Ndung’u, HIV Pathogenesis Programme, University of KwaZulu Natal, South Africa
James Kublin, HIV Vaccine Trials Network
Mboup Souleymane, Université Cheikh Anta DIOP, Senegal
Nina Russell, Bill & Melinda Gates Foundation
Mary Marovich, Vaccine Research Program, Division of AIDS, U.S. National Institutes of Health
Claire Rekacewicz, Agence Nationale de Recherche sur le Sida et les hépatites virales, France
Deenan Pillay, Africa Centre for Population Health, South Africa

Monday, 17 Oct: Engaging High Risk Fishing Communities

Engaging High Risk Fishing Communities in HIV Prevention Research

Monday, 17 October
Time: 12:00-15:00
Venue: Sheraton Grand Chicago, Chicago Ballroom X

This session will provide insights into the disproportionately high HIV incidence in fishing communities on the shores and islands of Lake Victoria, address their limited access to HIV services and health care in general, and discuss key questions in HIV prevention research, scale-up of anti-retroviral treatment and care interventions more broadly for and with these communities.

Session Chairs:
Anatoli Kamali, International AIDS Vaccine Initiative
Elizabeth Bukusi, Kenya Medical Research Institute

Saidi Kapiga, Mwanza Interventional Trials Unit, Uganda
Hannah Kibuukah, Makerere University Walter Reed Program
Zachary Kwena, Kenya Medical Research Institute
Noah Kiwanuka, Uganda Virus Research Institute-International AIDS Vaccine Initiative
Caitlin Kennedy, Johns Hopkins University

Monday, 17 Oct: Germline Targeting Immunogens

Germline Targeting Immunogens: Taking the First Steps Toward bNAb Development

Monday, 17 October
Time: 12:30-15:30
Venue: Sheraton Grand Chicago, Chicago Ballroom VIII

The emerging vaccine strategy of immunizing people with a series of different engineered HIV proteins as immunogens in order to teach the immune system to produce HIV bNAbs from germline B cells, has generated a great deal of interest and momentum. This session will introduce the fundamentals of this vaccine strategy, provide an update on current status and most recent, encouraging results, and look out at next development steps.

Session Chair:
William Schief, IAVI Neutralizing Antibody Center, The Scripps Research Institute (TSRI) and Ragon Institute of Massachusetts General Hospital, MIT and Harvard


William Schief, IAVI Neutralizing Antibody Center, TSRI and Ragon Institute of Massachusetts General Hospital, MIT and Harvard
Bart Haynes, Duke University Medical Center
Andrew McGuire, Stamatatos Lab, Fred Hutchinson Cancer Research Center
John Mascola, National Institutes of Health/Vaccine Research Center
Amelia Escolano, Nussenzweig Lab, Rockefeller University
Dennis Burton, IAVI Neutralizing Antibody Center, TSRI and Ragon Institute of Massachusetts General Hospital, MIT and Harvard
Peter Kwong, National Institutes of Health/Vaccine Research Center

Friday, 21 October: Systems Biology in HIV Vaccine Design

Systems Biology and Vaccines: Implications for HIV Vaccine Design

Friday, 21 October
Time: 9:00-11:30
Venue: Sheraton Grand Chicago, Sheraton Ballroom I
Co-hosts: Case Western Reserve University, Emory Vaccine Center, IAVI

Systems biology approaches can help identify predictors and genetic signatures of immunogenicity and protective immune responses. They can also help understand the impact nutrition, concomitant infections and the host microbiome on immune response to vaccines. This session will review current systems biology methodologies, examples of their use in vaccinology and immunology, and current research relevant to HIV vaccine development.

Session Chairs:
Bali Pulendran, Emory Vaccine Center
Rafick Sekaly, Case Western Reserve University


Elias Haddad, Drexel University
Scott Handley, Washington University
Bali Pulendran, Emory University
Julie McElrath, Fred Hutchinson Cancer Research Center and University of Washington
John Aitchison, Seattle Biomedical Research Institute

Click reception title for a map and full details

WEDNESDAY, 19 October: Progressing Together Toward an AIDS Vaccine

Date: Wednesday, 19 October
Time: 19:30-21:00
Venue: Bellwether Meeting House & Eatery, 302 East Illinois Street, one block north of the Sheraton
Co-hosts: IAVI, HIV Vaccine Trials Network, U.S. Military HIV Research Program, African AIDS Vaccine Virtual Network

Print Email